{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:14:45Z","timestamp":1767924885991,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012905","name":"Department of Science and Technology of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["DNA Repair"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.dnarep.2020.102940","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T02:43:03Z","timestamp":1595904183000},"page":"102940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["2-hexyl-4-pentynoic acid, a potential therapeutic for breast carcinoma by influencing RPA2 hyperphosphorylation-mediated DNA repair"],"prefix":"10.1016","volume":"95","author":[{"given":"Wenwen","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhendong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuchao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dnarep.2020.102940_bib0005","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/bjc.2013.21","article-title":"Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair","volume":"108","author":"Groselj","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dnarep.2020.102940_bib0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0973-1482.137937","article-title":"Epigenetic therapy of cancer with histone deacetylase inhibitors","volume":"10","author":"Lakshmaiah","year":"2014","journal-title":"J Can Res Ther"},{"key":"10.1016\/j.dnarep.2020.102940_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051027","article-title":"The effect of VPA on increasing radiosensitivity in osteosarcoma cells and primary-culture cells from chemical carcinogen-induced breast cancer in rats","volume":"18","author":"Liu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dnarep.2020.102940_bib0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1039\/C5TX00476D","article-title":"Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway","volume":"5","author":"Luo","year":"2016","journal-title":"Toxicol Res"},{"key":"10.1016\/j.dnarep.2020.102940_bib0030","first-page":"787","article-title":"Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation","volume":"37","author":"Kawano","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0035","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.18632\/oncotarget.6991","article-title":"Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia","volume":"7","author":"Leitch","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.dnarep.2020.102940_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2018.07.057","article-title":"Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer","volume":"835","author":"Heers","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00011","article-title":"Window-of-opportunity study of valproic acid in breast cancer testing a gene expression biomarker","author":"Cohen","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0050","doi-asserted-by":"crossref","first-page":"e0141266","DOI":"10.1371\/journal.pone.0141266","article-title":"Determination of the optimal concentration of valproic acid in patients with epilepsy: A population pharmacokinetic-pharmacodynamic analysis","volume":"10","author":"Nakashima","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dnarep.2020.102940_bib0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ana.410140107","article-title":"Plasma concentrations of sodium valproate: their clinical value","volume":"14","author":"Turnbull","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0060","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1021\/tx0502241","article-title":"Teratogenic effects mediated by inhibition of histone deacetylases: Evidence from quantitative structure activity relationships of 20 valproic acid derivatives","volume":"19","author":"Eikel","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2010.04.013","article-title":"Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction","volume":"476","author":"Leng","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.dnarep.2020.102940_bib0070","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1582-4934.2008.00271.x","article-title":"New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma","volume":"12","author":"Wedel","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.dnarep.2020.102940_bib0075","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bmcl.2008.02.007","article-title":"New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity","volume":"18","author":"Perrino","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.dnarep.2020.102940_bib0080","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ntt.2008.03.060","article-title":"Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity","volume":"30","author":"Gravemann","year":"2008","journal-title":"Neurotoxicol Teratol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0085","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dnarep.2020.102940_bib0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00280-009-0991-z","article-title":"Hydroxyurea and hydroxamic acid derivatives as antitumor drugs","volume":"64","author":"Saban","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/era.11.175","article-title":"Hydroxyurea: A key player in cancer chemotherapy","volume":"12","author":"Madaan","year":"2012","journal-title":"Expert Rev Anticanc"},{"key":"10.1016\/j.dnarep.2020.102940_bib0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood.V69.1.109.109","article-title":"Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia","volume":"69","author":"Charache","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.dnarep.2020.102940_bib0105","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13043","article-title":"Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience","volume":"32","author":"Cantisani","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.dnarep.2020.102940_bib0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09537100400020179","article-title":"Toxicity and side effects of hydroxyurea used for primary thrombocythemia","volume":"16","author":"Randi","year":"2005","journal-title":"Platelets"},{"key":"10.1016\/j.dnarep.2020.102940_bib0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1634\/theoncologist.3-5-289","article-title":"Breast cancer: high-dose therapy","volume":"3","author":"Subramanyan","year":"1998","journal-title":"The Oncologist"},{"key":"10.1016\/j.dnarep.2020.102940_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2017.08.002","article-title":"Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway","volume":"58","author":"Tian","year":"2017","journal-title":"DNA Repair"},{"key":"10.1016\/j.dnarep.2020.102940_bib0130","doi-asserted-by":"crossref","first-page":"39517","DOI":"10.1074\/jbc.M605121200","article-title":"RPA2 Is a direct downstream target for ATR to regulate the S-phase checkpoint","volume":"281","author":"Olson","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dnarep.2020.102940_bib0135","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/carcin\/bgq035","article-title":"The role of RPA2 phosphorylation in homologous recombination in response to replication arrest","volume":"31","author":"Shi","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.dnarep.2020.102940_bib0140","series-title":"Science","article-title":"China finally setting guidelines for treating lab animals","author":"McLaughlin","year":"2016"},{"key":"10.1016\/j.dnarep.2020.102940_bib0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.dnarep.2015.06.005","article-title":"p53 suppresses hyper-recombination by modulating BRCA1 function","volume":"33","author":"Dong","year":"2015","journal-title":"DNA Repair"},{"key":"10.1016\/j.dnarep.2020.102940_bib0150","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.leukres.2006.01.009","article-title":"Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells","volume":"30","author":"Deubzer","year":"2006","journal-title":"Leukemia Res"},{"key":"10.1016\/j.dnarep.2020.102940_bib0155","first-page":"3147","article-title":"The story of MCF-7 breast cancer cell line: 40 years of expereince in research","volume":"35","author":"Comsa","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.dnarep.2020.102940_bib0160","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.1073834","article-title":"Biallelic inactivation of BRCA2 in Fanconi anemia","volume":"297","author":"Howlett","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.dnarep.2020.102940_bib0165","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.molcel.2010.01.021","article-title":"Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair","volume":"37","author":"Petermann","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.dnarep.2020.102940_bib0170","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fonc.2014.00289","article-title":"A small-molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to doxorubicin","volume":"4","author":"Alagpulinsa","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0175","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1541-7786.MCR-05-0192","article-title":"The role of the BRCA1 tumor suppressor in DNA double-strand break repair","volume":"3","author":"Zhang","year":"2005","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.dnarep.2020.102940_bib0180","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3760\/cma.j.issn.0366-6999.20130276","article-title":"Establishment of novel rat models for premalignant breast disease","volume":"127","author":"Wang","year":"2014","journal-title":"Chin Med J"},{"key":"10.1016\/j.dnarep.2020.102940_bib0185","unstructured":"World Health Organization, Breast cancer, in: Cancer, WHO, nd."},{"key":"10.1016\/j.dnarep.2020.102940_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","article-title":"Overview of resistance to systemic therapy in patients with breast cancer","volume":"608","author":"Gonzalez-Angulo","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.dnarep.2020.102940_bib0195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2010.04.013","article-title":"Potent neuroprotective effects of novel structural derivatives of valproic acid:Potential roles of HDAC inhibition and HSP70 induction","volume":"476","author":"Leng","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.dnarep.2020.102940_bib0200","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrm2851","article-title":"Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis","volume":"11","author":"Moynahan","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.dnarep.2020.102940_bib0205","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/carcin\/bgq035","article-title":"The role of RPA2 phosphorylation in homologous recombination in response to replication arrest","volume":"31","author":"Shi","year":"2010","journal-title":"Carcinogenesis"},{"issue":"Pt 3","key":"10.1016\/j.dnarep.2020.102940_bib0210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1042\/BJ20050379","article-title":"Preferential localization of hyperphosphorylated replication protein A to double-strand break repair and checkpoint complexes upon DNA damage","volume":"391","author":"Wu","year":"2005","journal-title":"Biochem J"},{"issue":"19","key":"10.1016\/j.dnarep.2020.102940_bib0215","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/onc.2012.257","article-title":"DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair","volume":"32","author":"Serrano","year":"2013","journal-title":"Oncogene"}],"container-title":["DNA Repair"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568786420301890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568786420301890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:48:45Z","timestamp":1761598125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568786420301890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":43,"alternative-id":["S1568786420301890"],"URL":"https:\/\/doi.org\/10.1016\/j.dnarep.2020.102940","relation":{},"ISSN":["1568-7864"],"issn-type":[{"value":"1568-7864","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-hexyl-4-pentynoic acid, a potential therapeutic for breast carcinoma by influencing RPA2 hyperphosphorylation-mediated DNA repair","name":"articletitle","label":"Article Title"},{"value":"DNA Repair","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dnarep.2020.102940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102940"}}